Joanne Bryce Biography and Net Worth

CFO of Disc Medicine

Joanne Bryce, CPA brings 35+ years of financial expertise to her role at SiteOne, where she oversees finance and accounting activities. Prior to joining SiteOne, Joanne served as Disc Medicine’s Chief Financial Officer, where she led the company’s reverse merger and listing on the Nasdaq and raised over $500M in venture and public financings. Ms. Bryce was previously the Chief Financial Officer of Arkuda Therapeutics, a biotechnology company, head of finance in a consulting role to Dyne Therapeutics, and Chief Financial Officer of Quartet Medicine. Prior to Quartet, Ms. Bryce held Chief Financial Officer and other executive roles at several technology and communications companies, including Speedy Packets, WiTricity, Jingle Networks, and Narrative Communications where she was the finance lead in the sale of the company to At Home Corporation.

Joanne began her career at Arthur Andersen & Co., an accounting firm, holds a B.S. from Babson College, and is a certified public accountant licensed in the Commonwealth of Massachusetts.

What is Joanne Bryce's net worth?: The estimated net worth of Joanne Bryce is at least $110,025.00 as of December 5th, 2023. Bryce owns 2,500 shares of Disc Medicine stock worth more than $110,025 as of April 22nd. This net worth approximation does not reflect any other investments that Bryce may own. Learn More about Joanne Bryce's net worth.
How do I contact Joanne Bryce?: The corporate mailing address for Bryce and other Disc Medicine executives is 297 Boston Post Road #248, Wayland MA, 01778. Disc Medicine can also be reached via phone at 617-401-4400 and via email at ir@geminitherapeutics.com. Learn More on Joanne Bryce's contact information.
Has Joanne Bryce been buying or selling shares of Disc Medicine?: Joanne Bryce has not been actively trading shares of Disc Medicine in the last ninety days. Most recently, Joanne Bryce sold 2,541 shares of the business's stock in a transaction on Tuesday, December 5th. The shares were sold at an average price of $56.00, for a transaction totalling $142,296.00. Following the completion of the sale, the chief financial officer now directly owns 2,500 shares of the company's stock, valued at $140,000. Learn More on Joanne Bryce's trading history.
Who are Disc Medicine's active insiders?: Disc Medicine's insider roster includes Mona Ashiya (Director), Kevin Bitterman (Director), Joanne Bryce (CFO), Jean Franchi (CFO), Rahul Khara (Insider), Brian Macdonald (Insider), John Quisel (CEO), William Savage (Insider), Pamela Stephenson (Insider), William White (Director), and Jonathan Yu (COO). Learn More on Disc Medicine's active insiders.
Are insiders buying or selling shares of Disc Medicine?: During the last year, insiders at the sold shares 21 times. They sold a total of 447,850 shares worth more than $25,068,128.17. The most recent insider tranaction occured on March, 24th when Director Mona Ashiya sold 5,738 shares worth more than $310,483.18. Insiders at Disc Medicine own 4.2% of the company. Learn More about insider trades at Disc Medicine.
Information on this page was last updated on 3/24/2025.

Joanne Bryce Insider Trading History at Disc Medicine

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/5/2023	Sell	2,541	$56.00	$142,296.00	2,500
9/1/2023	Sell	1,000	$52.99	$52,990.00	1,260
8/1/2023	Sell	4,521	$49.91	$225,643.11	1,260
6/28/2023	Sell	10,072	$49.95	$503,096.40	1,260

Joanne Bryce Buying and Selling Activity at Disc Medicine

Disc Medicine Company Overview

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $44.01

$42.93

$45.39

50 Day Range

MA: $49.07

$34.28

$56.92

2 Week Range

Now: $44.01

$25.64

$68.73

Volume

455,734 shs

Average Volume

346,864 shs

Market Capitalization

$1.52 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77